AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

📈 Piper Sandler raised its price target on AbbVie (ABBV) from $294 to $298 on May 14.

⚖️ The firm retained an Overweight rating on AbbVie shares following the update.

💊 Investor interest is driven by AbbVie's extensive pipeline for inflammatory bowel disease (IBD).

📅 AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting in Chicago.

🔬 The research focused on real-world evidence and long-term results for SKYRIZI and RINVOQ therapies.

🧪 ASPIRE-CD study data showed 52-week follow-up results for risankizumab-treated Crohn's patients.

📉 Treated individuals demonstrated lasting improvements in liquid stools, bowel urgency, and abdominal pain.

🤝 Piper Sandler views management's pursuit of novel combination methods as a positive development.

🔍 The firm highlights R&D opportunities beneath the radar of the general investment market.

💼 AbbVie is described as a research-based biopharmaceutical company with global operations.

⚠️ The article includes unrelated promotional content regarding AI stocks and other investment picks.

📰 Additional links promote lists of undervalued dividend stocks and hedge fund strategies.

Bullish Signals
  • Piper Sandler raised its price target for AbbVie (NYSE: ABBV) to $298 from $294 on May 14, retaining an Overweight rating.
  • AbbVie submitted 18 abstracts on inflammatory bowel illnesses at the 2026 Digestive Disease Week Annual Meeting held in Chicago from May 2 to 5.
  • The ASPIRE-CD study demonstrated that risankizumab-treated individuals with moderately to highly active Crohn's disease had long-lasting improvements in liquid stools, bowel urgency, and abdominal pain.
  • Management's pursuit of novel combination methods in IBD is viewed as a positive development given the competitiveness of the IBD medication development landscape.
  • AbbVie possesses a variety of R&D shots-on-goal that remain beneath the radar of the general investment market.
Risk Factors
  • The article contains promotional content for other stocks, specifically mentioning 'BAC' and AI stocks with '10,000% upside potential', which may indicate a lack of focus or potential bias in the analysis of AbbVie.
  • The text includes generic marketing copy about 'Top 12 Undervalued Dividend Stocks' and '33 Stocks That Should Double in 3 Years', suggesting the primary purpose is lead generation rather than providing deep, critical financial analysis of AbbVie's specific risks.
  • There is a significant discrepancy in dates within the article, mentioning a meeting held in 'May 2 to 5' and returns calculated through 'February 18th, 2026', which implies the data may be hypothetical or the article is using future-dated scenarios that could mislead investors about current performance.
  • The article fails to mention any specific financial risks associated with AbbVie's reliance on its IBD pipeline, such as potential patent cliffs for SKYRIZI and RINVOQ or regulatory hurdles for new combination therapies.
Full Analysis
Piper Sandler raised its price target on AbbVie (NYSE: ABBV) to $298 from $294 on May 14, maintaining an Overweight rating. The analyst firm highlighted the company's extensive pipeline for inflammatory bowel disease (IBD) as a primary driver of investor interest. At the 2026 Digestive Disease Week Annual Meeting in Chicago, AbbVie presented 18 abstracts focusing on real-world evidence and long-term outcomes for its Crohn's disease and ulcerative colitis therapies, SKYRIZI and RINVOQ. Key data presented included 52-week follow-up results from the ASPIRE-CD study, which showed that patients with moderately to highly active Crohn's disease treated with risankizumab experienced sustained improvements in liquid stools, bowel urgency, and abdominal pain. Piper Sandler noted that management's focus on novel combination therapies for IBD is a positive development given the competitive landscape of drug development in this area. The firm also pointed to various research and development opportunities within AbbVie that may not be fully appreciated by the broader investment market.